BR112013020981A2 - ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244> - Google Patents

ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244>

Info

Publication number
BR112013020981A2
BR112013020981A2 BR112013020981A BR112013020981A BR112013020981A2 BR 112013020981 A2 BR112013020981 A2 BR 112013020981A2 BR 112013020981 A BR112013020981 A BR 112013020981A BR 112013020981 A BR112013020981 A BR 112013020981A BR 112013020981 A2 BR112013020981 A2 BR 112013020981A2
Authority
BR
Brazil
Prior art keywords
tnf
present
detection assays
drugs
autoantibody detection
Prior art date
Application number
BR112013020981A
Other languages
English (en)
Inventor
Linda Ohrmund
Scott Hauenstein
Sharat Singh
Shui Long Wang
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013020981A2 publication Critical patent/BR112013020981A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244> a presente invenção refere-se aos testes para detectar e medir a presença ou o nível de auto-anticorpos para fármacos terapêuticos anti-tnf<244> em uma amostra. a presente invenção é útil para optimização da terapia e monitorização de pacientes que recebem terapias de fármacos anti-tnf<244> para detectar a presença ou nível de anticorpos contra o fármaco. a presente invenção proporciona também os métodos para a seleção de terapia, optimizando a terapia, e/ou reduzindo a toxicidade em indivíduos que receberam anti-tnf<244> para o tratamento de doença ou distúrbio mediano por tnf.
BR112013020981A 2011-02-17 2012-02-16 ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244> BR112013020981A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444097P 2011-02-17 2011-02-17
US201161484594P 2011-05-10 2011-05-10
US201161496501P 2011-06-13 2011-06-13
PCT/US2012/025437 WO2012154253A1 (en) 2011-02-17 2012-02-16 ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS

Publications (1)

Publication Number Publication Date
BR112013020981A2 true BR112013020981A2 (pt) 2016-10-11

Family

ID=45809635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020981A BR112013020981A2 (pt) 2011-02-17 2012-02-16 ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244>

Country Status (17)

Country Link
US (1) US20140045276A1 (pt)
EP (1) EP2676137B1 (pt)
JP (1) JP6063398B2 (pt)
KR (1) KR20140008397A (pt)
CN (1) CN103502815B (pt)
AU (1) AU2012254150B2 (pt)
BR (1) BR112013020981A2 (pt)
CA (1) CA2827609A1 (pt)
DK (1) DK2676137T3 (pt)
ES (1) ES2530175T3 (pt)
HK (1) HK1191688A1 (pt)
IL (1) IL227853A (pt)
MX (1) MX343327B (pt)
RU (1) RU2013142278A (pt)
SG (1) SG192770A1 (pt)
WO (1) WO2012154253A1 (pt)
ZA (1) ZA201306950B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
EP2630495B1 (en) 2010-10-18 2017-02-08 Nestec S.A. Methods for determining anti-drug antibody isotypes
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
JP6279590B2 (ja) 2012-10-03 2018-02-14 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 酸性条件でアナライトを測定するための方法およびキット
JP2015532425A (ja) 2012-10-05 2015-11-09 ネステク ソシエテ アノニム 粘膜治癒を予測及びモニタリングするための方法
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
CA2908553A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3077818B1 (en) 2013-12-03 2020-02-05 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
EP4137816A1 (en) 2014-02-11 2023-02-22 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN104034896A (zh) * 2014-06-19 2014-09-10 华北制药集团新药研究开发有限责任公司 一种双抗体夹心elisa检测方法
EP3175242A4 (en) * 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
WO2016063204A1 (en) * 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
BR112017004810A2 (pt) * 2014-11-05 2017-12-12 Hoffmann La Roche imunoensaio
BR112017011545A2 (pt) 2014-12-05 2018-03-13 Nestec Sa ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
AU2016326757B2 (en) 2015-09-24 2022-09-01 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
ES2815224T3 (es) * 2015-11-06 2021-03-29 Promise Proteomics Un método para cuantificar anticuerpos terapéuticos
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN109791142B (zh) 2016-07-08 2022-11-29 W 健康公司 用于确定样品中治疗性单克隆抗体及其相应抗药物抗体的量的通用测定
JP7060510B2 (ja) * 2016-09-06 2022-04-26 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
CN112534263A (zh) * 2018-08-03 2021-03-19 百时美施贵宝公司 用于检测抗药抗体的方法
JP2020115139A (ja) * 2020-03-11 2020-07-30 国立大学法人千葉大学 血管炎の検査方法
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트
CN112362649A (zh) * 2020-11-09 2021-02-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
CN114236139A (zh) * 2021-12-30 2022-03-25 苏州和锐生物科技有限公司 一种TNF-α生物制剂的抗体检测试剂盒、制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5094740A (en) * 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
JP2002538170A (ja) * 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
AU4341502A (en) 2000-10-30 2002-06-11 Univ Michigan Nod2 nucleic acids and proteins
EP1330525B1 (en) 2000-10-30 2012-12-05 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
AU2002902A (en) 2000-11-14 2002-05-27 Techlab Inc Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7785818B2 (en) 2002-10-25 2010-08-31 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7439019B2 (en) 2003-11-03 2008-10-21 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction
WO2006004958A2 (en) * 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
JP2007147367A (ja) * 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
WO2008059515A2 (en) 2006-08-01 2008-05-22 Divyank Turakhia A system and method of generating related words and word concepts
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
CN101802618B (zh) 2007-07-13 2015-02-25 雀巢产品技术援助有限公司 利用基于抗体的阵列选择肺癌治疗药物
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
AU2008348252A1 (en) * 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
JP5634405B2 (ja) * 2008-10-07 2014-12-03 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 試料中のアナライトの検出のための半逐次アッセイ
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US8408369B2 (en) 2009-09-08 2013-04-02 GM Global Technology Operations LLC Bimetallic brake rotor
EP2491385B1 (en) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ621655A (en) * 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies

Also Published As

Publication number Publication date
HK1191688A1 (en) 2014-08-01
MX2013009570A (es) 2013-09-06
AU2012254150A1 (en) 2013-05-02
NZ614170A (en) 2015-04-24
WO2012154253A1 (en) 2012-11-15
EP2676137A1 (en) 2013-12-25
ZA201306950B (en) 2015-04-29
ES2530175T3 (es) 2015-02-26
JP6063398B2 (ja) 2017-01-18
CN103502815A (zh) 2014-01-08
US20140045276A1 (en) 2014-02-13
DK2676137T3 (en) 2015-01-19
MX343327B (es) 2016-11-01
IL227853A0 (en) 2013-09-30
JP2014508930A (ja) 2014-04-10
AU2012254150B2 (en) 2015-08-13
CA2827609A1 (en) 2012-11-15
IL227853A (en) 2017-07-31
SG192770A1 (en) 2013-09-30
KR20140008397A (ko) 2014-01-21
CN103502815B (zh) 2015-09-23
EP2676137B1 (en) 2014-12-31
RU2013142278A (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
BR112013020981A2 (pt) ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf&lt;244&gt;
BR112012009855A2 (pt) métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit
Di Franco¹ et al. Misdiagnosis in fibromyalgia: a multicentre study
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
BR112012033783A2 (pt) aparelho para detectar uma doença em um material biológico, aparelho que compreende dois microdispositivos, microdispositivo, aparelho para interagir com um material biológico, e, métodos para a fabricação de um microdispositivo, para detectar uma doença na sua fase inicial em um primeiro material, e para detectar informação dinâmica de um material biológico
BR112015012616A2 (pt) método para avaliação da presença ou risco de tumores de cólon
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
Zhang et al. The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer
BR112018016337A2 (pt) anticorpos monoclonais da proteína ns1 de vírus antidengue
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112015011359A8 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo, dispositivo de ensaio, kit de teste, produto de programa de computador, e aparelho
Abuaf et al. Comparison of CD63 upregulation induced by NSAIDs on basophils and monocytes in patients with NSAID hypersensitivity
NZ603780A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
BR112013027867A2 (pt) &#34;método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit&#34;
MX343324B (es) Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
Kezai et al. Association between schizophrenia and Toxoplasma gondii infection in Algeria
BR112015008042A2 (pt) diagnósticos complementares para terapia com inibidor de quinase da família tec
MX2015006852A (es) Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
BR112017004883A2 (pt) ensaio de diagnóstico baseado em fragmento de rgma
Schlaeger et al. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?
IN2014DN08537A (pt)
Killoran et al. Biomarkers for Huntington's disease: A brief overview
BR112013014195A2 (pt) Método para a identificação de um paciente, composição, uso de bevacizumabe para a preparação de uma composição farmacêutica, método para o tratamento de um distúrbio proliferativo e composição, uso ou método

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]